ArticleJournal of tropical medicine2025
Article in Journal of tropical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr nuclear antigen 1 (EBNA1) is an attractive therapeutic target for identifying pharmaceutical drug molecules to fight Epstein-Barr virus (EBV) contagion because of its key function in viral reproduction. To find potent EBNA1 inhibitors, the Naturally Occurring Plant-based Anticancer Compound-Activity-Target (NPACT) database, including > 1500 compounds, was filtered utilizing computational approaches. The efficiency of the docking technique used to anticipate the inhibitor-EBNA1 binding pose was initially evaluated based on obtainable experimental data. Upon the computed docking scores, molecular dynamics simulations (MDSs) were executed for the most superior NPACT compounds bound to EBNA1, accompanied by binding affinity estimations utilizing the MM/GBSA approach. According to binding affinity computations over 200 ns MDS, bitucarpin A demonstrated stronger Δ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.